BridgeBio (BBIO) Director Jennifer Cook Exercises Options, Sells Shares

What Happened

• Jennifer E. Cook, a director of BridgeBio Pharma (BBIO), exercised stock options on July 9, 2026 for a total of 148,589 shares (three option tranches) at strikes of $8.45, $29.00 and $16.75, costing $3,708,335.
• The same day she sold 36,167 shares at $84.00 and 112,422 shares at $90.00, generating total sale proceeds of $13,156,008. The filing shows the option-to-share conversion entries (derivative dispositions at $0) consistent with exercising the options and then selling the shares.

Key Details

• Transaction date: July 9, 2026; Form 4 filed July 13, 2026.
• Exercise details: 19,000 @ $8.45 ($160,550); 112,422 @ $29.00 ($3,260,238); 17,167 @ $16.75 ($287,547). Total exercise cost = $3,708,335.
• Sales: 36,167 @ $84.00 ($3,038,028); 112,422 @ $90.00 ($10,117,980). Total proceeds = $13,156,008.
• The filing includes zero-dollar derivative dispositions that reflect conversion of options into shares upon exercise.
• Footnote: Sales were effected under a Rule 10b5-1 trading plan adopted March 16, 2026.
• Vesting notes (from the filing): the exercised options were subject to earlier vesting schedules (footnotes indicate vesting dates in 2023–2026), i.e., the exercised options were vested and exercisable.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing timing: reported on July 13 for July 9 transactions (the filing date is shown on the Form 4).

Context

• This is an option exercise followed by immediate open-market sales (a common “exercise-and-sell” or cashless-like sequence): the director exercised vested options, then sold the resulting shares the same day.
• Sales under a pre-established 10b5-1 plan typically indicate pre-planned dispositions rather than ad-hoc trades; Form 4 notes the plan adoption date.
• These are director-level transactions (not a 10% owner or CEO disclosure) and should be viewed as realized monetization of vested equity rather than an explicit commentary on company fundamentals.